The response to first-line, platinum-based treatment of muscle-invasive bladder cancer has not improved in 3 decades.
To identify genes that influence cisplatin resistance in bladder cancer.
We performed a whole-genome CRISPR screen in a bladder cancer cell line to identify genes that mediate resistance to cisplatin.